{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-060518","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.592125+00:00","generated_at":"2026-06-02T02:12:06.569991+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Annovis AD Phase II/III shows significant cognition improvement; PD topline due June 2024; Q1 cash $3.1M","bullets":["Q1 2024 cash $3.1M vs $5.8M at Dec 31, 2023; runway into Q4 2024. Operating expenses $7.8M (R&D $6.5M, G&A $1.3M).","Phase II/III AD: ADAS-Cog 11 improvement 3.3 pts vs 0.3 for placebo at 3 months; plan 18-month Phase III trial.","PD Phase III unblinded; topline results expected June 2024; 523 patients randomized, 471 completed.","Net loss per share $0.10 basic, $0.72 diluted; includes $6.7M non-cash gain from warrant revaluation.","Filed patent application for buntanetap in neuropsychiatric disorders including autism, ADHD, depression."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-060518","json":"https://secwatch.observer/filing/0001104659-24-060518.json","markdown":"https://secwatch.observer/filing/0001104659-24-060518.md","text":"https://secwatch.observer/filing/0001104659-24-060518.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924060518/0001104659-24-060518-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924060518/tm2414281d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:12:06.569991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52dedb3b60dc640fd4f99d70e04ebee55aac6aa5","claim":"Annovis Bio, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 13, 2024, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924060518/0001104659-24-060518-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}